Source: Fortune.com
Summary
Charlotte Touzalin, an 18-year-old college student, and her mom, Anne Schultz, were diagnosed with polyendocrine metabolic ovarian syndrome (PMOS), a hormonal condition affecting 1 in 8 women worldwide. They struggled with weight gain, abnormal periods, and unwanted facial hair for years before finding a diagnosis. Touzalin participated in a study testing GLP-1 drugs, which showed promising results in improving symptoms, including weight loss, insulin resistance, and hormone balance. Researchers believe GLP-1s may be an effective treatment for PMOS, but insurance coverage is often a barrier.
Our Reading
The numbers tell one story.
GLP-1 drugs are being tested as a treatment for PMOS, a hormonal condition affecting 1 in 8 women worldwide. Researchers like Dr. Melanie Cree are finding these drugs “incredibly effective” in improving symptoms. However, insurance coverage is often a problem, and doctors are prescribing the drugs “off label” for PMOS. The story of Charlotte Touzalin and her mom, Anne Schultz, highlights the struggles of living with PMOS and the potential benefits of GLP-1s.
The announcement sounds familiar: a promising treatment is available, but access is limited by insurance coverage. The strategy enters a familiar phase: doctors are using the treatment “off label,” and patients are fighting for access.
The original observation: “It’s something that could help a lot of other people,” said Touzalin, highlighting the potential of GLP-1s for PMOS patients.
Author: Evan Null
